Preterm labor: Current pharmacotherapy options for tocolysis

Expert Opinion on Pharmacotherapy

Volumn 15, Issue 6, 2014, Pages 787-797

  Van Vliet, Elvira O G ^a   Boormans, Elisabeth M ^b   De Lange, Thomas S ^c   Mol, Ben W ^c   Oudijk, Martijn A ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b ACADEMIC MEDICAL CENTER   (Netherlands)

^c UNIVERSITY OF ADELAIDE   (Australia)

Author keywords

Pharmacotherapy; Preterm birth; Preterm labor; Tocolytics

Indexed keywords

ATOSIBAN; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; CALCIUM CHANNEL BLOCKING AGENT; GESTAGEN; MAGNESIUM SULFATE; NIFEDIPINE; OXYTOCIN ANTAGONIST; PROGESTERONE; PROSTAGLANDIN SYNTHASE INHIBITOR; UTERUS SPASMOLYTIC AGENT;

ADVERSE OUTCOME; DRUG EFFICACY; DRUG SAFETY; DYSPNEA; FETUS LUNG MATURATION; FLUSHING; GESTATIONAL AGE; HEADACHE; HEART PALPITATION; HUMAN; HYPOTENSION; LUNG EDEMA; MAINTENANCE THERAPY; NAUSEA; NEWBORN INTENSIVE CARE; NEWBORN MORBIDITY; NEWBORN MORTALITY; PREMATURE FETUS MEMBRANE RUPTURE; PREMATURE LABOR; REVIEW; SIDE EFFECT; TACHYCARDIA; THORAX PAIN; TOCOLYSIS; TREATMENT OUTCOME; TREMOR; VOMITING;

FEMALE; HUMANS; INFANT, NEWBORN; NIFEDIPINE; OBSTETRIC LABOR, PREMATURE; PREGNANCY; PREMATURE BIRTH; PROGESTERONE; PROGESTINS; TOCOLYSIS; TOCOLYTIC AGENTS; VASOTOCIN;

EID: 84896460563     PISSN: 14656566     EISSN: 17447666     Source Type: Journal    
DOI: 10.1517/14656566.2014.889684     Document Type: Review

References (71)

1. Goldenberg RL, Culhane JF, Iams JD, Romero R. Epidemiology and causes of preterm birth. Lancet 2008;371:75-84
2. Landelijke Neonatale Registratie 2003. Dutch Neonatal Database 2002. Prismant 2002
3. Petrou S, Eddama O, Mangham L. A structured review of the recent literature on the economic consequences of preterm birth. Arch Dis Child Fetal Neonatal Ed 2011;96:225-32
4. Romero R, Espinoza J, Kusanovic JP, et al. The preterm parturition syndrome. BJOG 2006;113:17-42
5. de Laat MW, Pieper PG, Oudijk MA, et al. The clinical and molecular relations between idiopathic preterm labor and maternal congenital heart defects. Reprod Sci 2013;20:190-201
6. Roberts D, Dalziel Z. Antenatal corticosteroids for accelerating fetal lung maturation for women at risk of preterm birth. Cochrane Database Syst Rev 2006;(3):CD004454
7. Huszar G, Roberts JM. Biochemistry and pharmacology of the myometrium and labor: regulation at the cellular and molecular levels. Am J Obstet Gynecol 1982;142:225-37
8. Anotayanonth S, Subhedar NV, Garner P, et al. Betamimetics for inhibiting preterm labour. Cochrane Database Syst Rev 2004;(4):CD004352
9. Papatsonis D, Flenady V, Cole S, Liley H. Oxytocin receptor antagonists for inhibiting preterm labour. Cochrane Database Syst Rev 2005;(3):CD004452
10. Haas DM, Caldwell DM, Kirkpatrick P, et al. Tocolytic therapy for preterm delivery: systematic review and network meta-Analysis. BMJ 2012;345:e6226
11. de Heus R, Mol BW, Erwich JJ, et al. Adverse drug reactions to tocolytic treatment for preterm labour: prospective cohort study. BMJ 2009;338:b744
12. Hayes E, Moroz L, Pizzi L, Baxter J. A cost decision analysis of 4 tocolytic drugs. Am J Obstet Gynecol 2007;197:383.e1-6
13. King JF, Flenady VJ, Papatsonis DN, et al. Calcium channel blockers for inhibiting preterm labour. Cochrane Database Syst Rev 2003;(1):CD002255
14. Lyndrup J, Lamont RF. The choice of a tocolytic for the treatment of preterm labor: a critical evaluation of nifedipine versus atosiban. Expert Opin Investig Drugs 2007;16:843-53
15. Lamont RF, Khan KS, Beattie B, et al. The quality of nifedipine studies used to assess tocolytic efficacy: a systematic review. J Perinat Med 2005;33:287-95
16. Salim R, Garmi G, Nachum Z, et al. Nifedipine compared with atosiban for treating preterm labor: a randomized controlled trial. Obstet Gynecol 2012;120:1323-31
17. Klauser CK, Briery CM, Martin RW, et al. A comparison of three tocolytics for preterm labor: a randomized clinical trial. J Matern Fetal Neonatal Med 2013. [Epub ahead of print]
18. Klauser CK, Briery CM, Keiser SD, et al. Effect of antenatal tocolysis on neonatal outcomes. J Matern Fetal Neonatal Med 2012;25:2778-81
19. Khan K, Zamora J, Lamont RF, et al. Safety concerns for the use of calcium channel blockers in pregnancy for the treatment of spontaneous preterm labour and hypertension: a systematic review and meta-regression analysis. J Matern Fetal Neonatal Med 2010;23:1030-8
20. van Veen AJ, Pelinck MJ, van Pampus MG, Erwich JJ. Severe hypotension and fetal death due to tocolysis with nifedipine. BJOG 2005;112:509-10
21. Papatsonis DN, Carbonne B, Dekker GA, et al. Severe hypotension and fetal death due to tocolysis with nifedipine. BJOG 2005;112:1582-3
22. Houtzager BA, Hogendoorn SM, Papatsonis DN, et al. Long-term follow up of children exposed in utero to nifedipine or ritodrine for the management of preterm labour. BJOG 2006;113:324-31
23. Coomarasamy A, Knox EM, Gee H, et al. Effectiveness of nifedipine versus atosiban for tocolysis in preterm labour: a meta-Analysis with an indirect comparison of randomised trials. BJOG 2003;110:1045-9
24. Available from: www.studies-obsgyn.nl
25. Husslein P, Roura L, Dudenhausen J, et al. Clinical practice evaluation of atosiban in preterm labour management in six European countries. BJOG 2006;113:105-10
26. Seinen LH, Simons SO, van der Drift MA, et al. Maternal pulmonary oedema due to the use of atosiban in cases of multiple gestation. Ned Tijdschr Geneeskd 2013;157:A5316
27. The Worldwide Atosiban versus Beta-Agonists Study Group Participants. Effectiveness and safety of the oxytocin antagonist atosiban versus beta-Adrenergic agonists in the treatment of preterm labour. BJOG 2001;108:133-42
28. Romero R, Sibai BM, Sanchez-Ramos L, et al. An oxytocin receptor antagonist (atosiban) in the treatment of preterm labor: a randomized, double-blind, placebo-controlled trial with tocolytic rescue. Am J Obstet Gynecol 2000;182:1173-83
29. Wex J, Abou-Setta AM, Clerici G, Di Renzo GC. Atosiban versus betamimetics in the treatment of preterm labour in Italy: clinical and economic importance of side-effects. Eur J Obstet Gynecol Reprod Biol 2011;157:128-35
30. Pierzynski P, Lemancewicz A, Reinheimer T, et al. Inhibitory effect of barusiban and atosiban on oxytocin-induced contractions of myometrium from preterm and term pregnant women. J Soc Gynecol Investig 2004;11:384-7
31. Thornton S, Goodwin TM, Greisen G, et al. The effect of barusiban, a selective oxytocin antagonist, in threatened preterm labor at late gestational age: a randomized, double-blind, placebo-controlled trial. Am J Obstet Gynecol 2009;200:627.e1-10
32. 1a receptor antagonist, on uterine contractions in preterm labor. Gynecol Endocrinol 2005;20:104-9
33. King J, Flenady V, Cole S, Thornton S. Cyclo-oxygenase (COX) inhibitors for treating preterm labour. Cochrane Database Syst Rev 2005;(2):CD001992
34. Crowther CA, Hiller JE, Doyle LW. Magnesium sulphate for preventing preterm birth in threatened preterm labour. Cochrane Database Syst Rev 2002;(4):CD001060
35. Doyle LW, Crowther CA, Middleton P, et al. Magnesium sulphate for women at risk of preterm birth for neuroprotection of the fetus. Cochrane Database Syst Rev 2009;(1):CD004661
36. Bain E, Middleton P, Crowther CA. Different magnesium sulphate regimens for neuroprotection of the fetus for women at risk of preterm birth. Cochrane Database Syst Rev 2012;2(2):CD009302
37. Koontz SL, Friedman SA, Schwartz ML. Symptomatic hypocalcemia after tocolytic therapy with magnesium sulfate and nifedipine. Am J Obstet Gynecol 2004;190:1773-6
38. Garfield RE, Kannan MS, Daniel EE. Gap junction formation in myometrium: control by estrogens, progesterone, and prostaglandins. Am J Physiol 1980;238:C81-9
39. Hendrix EM, Myatt L, Sellers S, et al. Steroid hormone regulation of rat myometrial gap junction formation: effects on cx43 levels and trafficking. Biol Reprod 1995;52:547-60
40. Jayasooriya GS, Lamont RF. The use of progesterone and other progestational agents to prevent spontaneous preterm labour and preterm birth. Expert Opin Pharmacother 2009;10:1007-16
41. Keirse MJ. Progestogen administration in pregnancy may prevent preterm delivery. Br J Obstet Gynaecol 1990;97:149-54
42. Saleh Gargari S, Habibolahi M, Zonobi Z. Outcome of vaginal progesterone as a tocolytic agent: randomized clinical trial. ISRN Obstet Gynecol 2012;2012:607906
43. Di Renzo GC, Rosati A, Mattei A, et al. The changing role of progesterone in preterm labour. BJOG 2005;112:57-60
44. Facchinetti F, Paganelli S, Comitini G, et al. Cervical length changes during preterm cervical ripening: effects of 17-Alpha-hydroxyprogesterone caproate. Am J Obstet Gynecol 2007;196:453-4
45. Noblot G, Audra P, Dargent D, et al. The use of micronized progesterone in the treatment of menace of preterm delivery. Eur J Obstet Gynecol Reprod Biol 1991;40:203-9
46. Chanrachakul B, Broughton Pipkin F, Warren AY, et al. Progesterone enhances the tocolytic effect of ritodrine in isolated pregnant human myometrium. Am J Obstet Gynecol 2005;192:458-63
47. Borna S, Sahabi N. Progesterone for maintenance tocolytic therapy after threatened preterm labour: a randomised controlled trial. Aust NZ J. Obstet Gynaecol 2008;48:58-63
48. Rozenberg P, Chauveaud A, Deruelle P, et al. Prevention of preterm delivery after successful tocolysis in preterm labor by 17 alpha- hydroxyprogesterone caproate: a randomized controlled trial. Am J Obstet Gynecol 2012;206:206-9
49. da Fonseca EB, Bittar RE, Carvalho MH, Zugaib M. Prophylactic administration of progesterone by vaginal suppository to reduce the incidence of spontaneous preterm birth in women at increased risk: a randomized placebo-controlled double-blind study. Am J Obstet Gynecol 2003;188:419-24
50. Meis PJ, Klebanoff M, Thom E, et al. Prevention of recurrent preterm delivery by 17 alpha-hydroxyprogesterone caproate. N Engl J Med 2003;348:2379-85
51. Hassan SS, Romero R, Vidyadhari D, et al. Vaginal progesterone reduces the rate of preterm birth in women with a sonographic short cervix: a multicenter, randomized, double-blind, placebo-controlled trial Ultrasound Obstet Gynecol 2011;38:18-31
52. Su LL, Samuel M, Chong YS. Progestational agents for treating threatened or established preterm labour. Cochrane Database Syst Rev 2010;(1):CD006770
53. Romero R, Nicolaides K, Conde-Agudelo A, et al. Vaginal progesterone in women with an asymptomatic sonographic short cervix in the midtrimester decreases preterm delivery and neonatal morbidity: a systematic review and metaanalysis of individual patient data. Am J Obstet Gynecol 2012;206:124.e1-19
54. Schuit E, Stock S, Groenwold RH, et al. Progestogens to prevent preterm birth in twin pregnancies: an individual participant data meta-Analysis of randomized trials. BMC Pregnancy Childbirth 2012;12:13
55. Resseguie LJ, Hick JF, Bruen JA, et al. Congenital malformations among offspring exposed in utero to progestins, olmsted county, minnesota, 1936-1974. Fertil Steril 1985;43:514-19
56. Yovich JL, Turner SR, Draper R. Medroxyprogesterone acetate therapy in early pregnancy has no apparent fetal effects. Teratology 1988;38:135-44
57. Katz Z, Lancet M, Skornik J, et al. Teratogenicity of progestogens given during the first trimester of pregnancy. Obstet Gynecol 1985;65:775-80
58. Mulder EJ, Versteegh EM, Bloemenkamp KW, et al. Does 17-A- hydroxyprogesterone caproate affect fetal biometry and birth weight in twin pregnancy? Ultrasound Obstet Gynecol 2013;42:329-34
59. Assessment of Perinatal Outcome by use of Specific Tocolytics in Early Labour (APOSTEL III)-NTR 2947. Available from: www.trialregister.nl.
60. Roos C, Spaanderman ME, Schuit E, et al. Effect of maintenance tocolysis with nifedipine in threatened preterm labor on perinatal outcomes: a randomized controlled trial. JAMA 2013;309:41-7
61. Valenzuela GJ, Sanchez-Ramos L, Romero R, et al. Maintenance treatment of preterm labor with the oxytocin antagonist atosiban. The atosiban PTL-098 study group. Am J Obstet Gynecol 2000;182:1184-90
62. Han S, Crowther CA, Moore V. Magnesium sulphate for preventing preterm birth after threatened preterm labour. Cochrane Database Syst Rev 2013;(5):CD000940
63. Arikan I, Barut A, Harma M, Harma IM. Effect of progesterone as a tocolytic and in maintenance therapy during preterm labor. Gynecol Obstet Invest 2011;72:269-73
64. Aagaard-Tillery KM, Nuthalapaty FS, Ramsey PS, Ramin KD. Preterm premature rupture of membranes: perspectives surrounding controversies in management. Am J Perinatol 2005;22:287-97
65. Ehsanipoor RM, Shrivastava VK, Lee RM, et al. A randomized, double-masked trial of prophylactic indomethacin tocolysis versus placebo in women with premature rupture of membranes. Am J Perinatol 2011;28:473-8
66. Shinjo A, Otsuki K, Sawada M, et al. Retrospective cohort study: a comparison of two different management strategies in patients with preterm premature rupture of membranes. Arch Gynecol Obstet 2012;286:337-45
67. Assessment of perinatal outcome by use of specific tocolytics in early labour (APOSTEL VI)-NTR 3363. Available from: www.trialregister.nl.
68. Goya M, Pratcorona L, Merced C, et al. Cervical pessary in pregnant women with a short cervix (PECEP): an open-label randomised controlled trial. Lancet 2012;379:1800-6
69. Liem S, Schuit E, Hegeman M, et al. Cervical pessaries for prevention of preterm birth in women with a multiple pregnancy (ProTWIN): a multicentre, open-label randomised controlled trial. Lancet 2013;382:1341-9
70. Vis JY, Wilms FF, Oudijk MA, et al. Cost-effectiveness of fibronectin testing in a triage in women with threatened preterm labor: alleviation of pregnancy outcome by suspending tocolysis in early labor (APOSTEL-I trial). BMC Pregnancy Childbirth 2009;9:38
71. Roberts D, Dalziel S. Antenatal corticosteroids for accelerating fetal lung maturation for women at risk of preterm birth. Cochrane Database Syst Rev 2006;(3):CD004454